Sign in or Register   Sign in or Register
  |  

Mouse Anti-EGR2 (AA 217-293) Recombinant Antibody (CBFYE-0611) (CBMAB-E1008-FY)

This product is mouse antibody that recognizes EGR2. The antibody CBFYE-0611 can be used for immunoassay techniques such as: WB, IP, ELISA.
See all EGR2 antibodies

Summary

Host Animal
Mouse
Specificity
Mouse, Rat, Human
Clone
CBFYE-0611
Antibody Isotype
IgG2b, κ
Application
WB, IP, ELISA

Basic Information

Immunogen
EGR2 partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Immunogen sequence: PGLFPMIPDY PGFFPSQCQR DLHGTAGPDR KPFPCPLDTL RVPPPLTPLS TIRNFTLGGP SAGVTGPGAS GGSEGPR
Specificity
Mouse, Rat, Human
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.2
Concentration
0.1 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
AA 217-293

Target

Full Name
early growth response 2 (Krox-20 homolog, Drosophila)
Introduction
The protein encoded by this gene is a transcription factor with three tandem C2H2-type zinc fingers. Defects in this gene are associated with Charcot-Marie-Tooth disease type 1D (CMT1D), Charcot-Marie-Tooth disease type 4E (CMT4E), and with Dejerine-Sottas syndrome (DSS). Multiple transcript variants encoding two different isoforms have been found for this gene.
Entrez Gene ID
Human1959
Mouse13654
Rat114090
UniProt ID
HumanP11161
MouseP08152
RatP51774
Alternative Names
Early Growth Response 2; Early Growth Response Protein 2; Zinc Finger Protein Krox-20; KROX20; AT591; KROX-20, Drosophila, Homolog (Early Growth Response-2); Early Growth Response 2 (Krox-20 Homolog, Drosophila)
Research Area
Sequence-specific DNA-binding transcription factor (PubMed:17717711).

Plays a role in hindbrain segmentation by regulating the expression of a subset of homeobox containing genes and in Schwann cell myelination by regulating the expression of genes involved in the formation and maintenance of myelin (By similarity).

Binds to two EGR2-consensus sites EGR2A (5'-CTGTAGGAG-3') and EGR2B (5'-ATGTAGGTG-3') in the HOXB3 enhancer and promotes HOXB3 transcriptional activation (By similarity).

Binds to specific DNA sites located in the promoter region of HOXA4, HOXB2 and ERBB2 (By similarity).

Regulates hindbrain segmentation by controlling the expression of Hox genes, such as HOXA4, HOXB3 and HOXB2, and thereby specifying odd and even rhombomeres (By similarity).

Promotes the expression of HOXB3 in the rhombomere r5 in the hindbrain (By similarity).

Regulates myelination in the peripheral nervous system after birth, possibly by regulating the expression of myelin proteins, such as MPZ, and by promoting the differentiation of Schwann cells (By similarity).

Involved in the development of the jaw openener musculature, probably by playing a role in its innervation through trigeminal motor neurons (By similarity).

May play a role in adipogenesis, possibly by regulating the expression of CEBPB (By similarity).

E3 SUMO-protein ligase helping SUMO1 conjugation to its coregulators NAB1 and NAB2, whose sumoylation down-regulates EGR2 transcriptional activity.
Biological Process
Brain development Source: ProtInc
Brain segmentation Source: Ensembl
Cellular response to organic substance Source: Ensembl
Facial nerve structural organization Source: UniProtKB
Fat cell differentiation Source: BHF-UCL
Gene expression Source: Ensembl
Learning or memory Source: Ensembl
Motor neuron axon guidance Source: Ensembl
Myelination Source: Ensembl
Peripheral nervous system development Source: ProtInc
Positive regulation of myelination Source: UniProtKB
Positive regulation of Schwann cell differentiation Source: UniProtKB
Positive regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of transcription by RNA polymerase II Source: UniProtKB
Protein export from nucleus Source: UniProtKB
Protein sumoylation Source: ARUK-UCL
Regulation of neuronal synaptic plasticity Source: Ensembl
Regulation of ossification Source: Ensembl
Regulation of transcription by RNA polymerase II Source: GO_Central
Response to insulin Source: Ensembl
Rhombomere 3 formation Source: Ensembl
Rhombomere 3 structural organization Source: UniProtKB
Rhombomere 5 formation Source: Ensembl
Rhombomere 5 structural organization Source: UniProtKB
Rhythmic behavior Source: Ensembl
Schwann cell differentiation Source: UniProtKB
Skeletal muscle cell differentiation Source: UniProtKB
Cellular Location
Nucleus
Involvement in disease
Neuropathy, congenital hypomyelinating, 1, autosomal recessive (CHN1):
The disease is caused by variants affecting the gene represented in this entry. Patients affected by the amyelinating form carry a causative, homozygous deletion encompassing a myelin-specific enhancer of EGR2 (PubMed:22522483). A severe degenerating neuropathy that results from a congenital impairment in myelin formation. It is clinically characterized by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities (as low as 3m/s). Some patients manifest nearly complete absence of spontaneous limb movements, respiratory distress at birth, and complete absence of myelin shown by electron microscopy of peripheral nerves.
Charcot-Marie-Tooth disease 1D (CMT1D):
A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.
Dejerine-Sottas syndrome (DSS)Z:
A severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. Characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.
PTM
Ubiquitinated by WWP2 leading to proteasomal degradation.
Acetylated at Lys-247. May be deacetylated by HDAC6, HDAC10 or SIRT1.

Masle-Farquhar, E., Peters, T. J., Miosge, L. A., Parish, I. A., Weigel, C., Oakes, C. C., ... & Goodnow, C. C. (2022). Uncontrolled CD21low age-associated and B1 B cell accumulation caused by failure of an EGR2/3 tolerance checkpoint. Cell Reports, 38(3), 110259.

Mendes, K., Schmidhofer, S., Minderjahn, J., Glatz, D., Kiesewetter, C., Raithel, J., ... & Rehli, M. (2021). The epigenetic pioneer EGR2 initiates DNA demethylation in differentiating monocytes at both stable and transient binding sites. Nature communications, 12(1), 1-15.

Cao, X., Ma, Q., Wang, B., Qian, Q., Liu, N., Liu, T., & Dong, X. (2021). Silencing long non-coding RNA MIAT ameliorates myocardial dysfunction induced by myocardial infarction via MIAT/miR-10a-5p/EGR2 axis. Aging (Albany NY), 13(8), 11188.

Ying, Y., Ma, X., Fang, J., Chen, S., Wang, W., Li, J., ... & Xie, L. (2021). EGR2-mediated regulation of m6A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization. Cell death & disease, 12(8), 1-12.

McCowan, J., Fercoq, F., Kirkwood, P. M., T’jonck, W., Hegarty, L. M., Mawer, C. M., ... & Bain, C. C. (2021). The transcription factor EGR2 is indispensable for tissue-specific imprinting of alveolar macrophages in health and tissue repair. Science immunology, 6(65), eabj2132.

Tyler, E. J., Gutierrez del Arroyo, A., Hughes, B. K., Wallis, R., Garbe, J. C., Stampfer, M. R., ... & Bishop, C. L. (2021). Early growth response 2 (EGR2) is a novel regulator of the senescence programme. Aging cell, 20(3), e13318.

Daniel, B., Czimmerer, Z., Halasz, L., Boto, P., Kolostyak, Z., Poliska, S., ... & Nagy, L. (2020). The transcription factor EGR2 is the molecular linchpin connecting STAT6 activation to the late, stable epigenomic program of alternative macrophage polarization. Genes & development, 34(21-22), 1474-1492.

Zang, C. S., Huang, H. T., Qiu, J., Sun, J., Ge, R. F., & Jiang, L. W. (2020). MiR-224-5p targets EGR2 to promote the development of papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci, 24(9), 4890-4900.

Liao, J., & Hargreaves, D. C. (2020). The alternative macrophage relay: STAT6 passes the baton to EGR2. Genes & Development, 34(21-22), 1407-1409.

Chen, M., Fan, L., Zhang, S. M., Li, Y., Chen, P., Peng, X., ... & Li, P. D. (2019). LINC01939 inhibits the metastasis of gastric cancer by acting as a molecular sponge of miR-17-5p to regulate EGR2 expression. Cell death & disease, 10(2), 1-13.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-EGR2 (AA 217-293) Recombinant Antibody (CBFYE-0611)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare